Aequus Pharmaceuticals (TSE:AQS) has released an update.
Aequus Pharmaceuticals Inc. reports a record-breaking sales quarter for Zimed® PF, the first preservative-free prostaglandin analog for glaucoma in Canada, signaling strong clinician adoption and patient benefit. As a specialty pharmaceutical company, Aequus focuses on developing and commercializing differentiated products in areas such as Ophthalmology and Optometry. Zimed® PF, approved by Health Canada in December 2022, addresses the needs of glaucoma and ocular hypertension patients, offering a preservative-free treatment option.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.
